A white blood cell, the TREM2/APOE/C1Q-positive macrophage, has been identified as a potential biomarker to predict recurrence of the most common type of kidney cancer and as a possible target for drug development.

A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.

The Kidney Cancer Association is recognizing the research accomplishments and leadership achievements of W. Kimryn Rathmell, MD, PhD, with its top honor, the Eugene P. Schonfeld Award.

The discovery that kidney cells with mutations in a certain gene are sensitive to therapies called PI3K inhibitors opens new opportunities for applying precision medicine to cancer treatment.

W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.

Vanderbilt-Ingram Cancer Center (VICC) will sponsor an educational conference for kidney cancer patients, survivors and family members Saturday, Sept. 9, 8 a.m. – 2 p.m., in the Preston Research Building, Suite 898.

Kidney cancer patients, family members, health care providers and members of the public are invited to attend a free educational workshop about the disease to be held at Vanderbilt-Ingram Cancer Center (VICC).